newsfilter
← Latest News
Business Wire·

Alzamend Neuro Announces Termination of At-the-Market Equity Offering Program

Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major